The oncology landscape is undergoing a significant strategic consolidation as major pharmaceutical players align their pipelines to maximize the therapeutic…
Read More
Daiichi Sankyo and Merck Voluntarily Withdraw US Application for Lung Cancer Drug Ifinatamab Deruxtecan Following FDA Discussions
Pharmaceutical giants Daiichi Sankyo and Merck & Co., known globally as MSD, have officially announced the voluntary withdrawal of their…
Read More
Daiichi Sankyo Partners with Waiv to Accelerate Digital Pathology Biomarker Discovery for Antibody-Drug Conjugate Programs
In a strategic move to enhance precision in oncology drug development, Japanese pharmaceutical giant Daiichi Sankyo has announced a significant…
Read More
Daiichi Sankyo Partners with Interna Therapeutics to Revolutionize Targeted Drug Delivery with Molecular Nano Motor Technology
Boston, MA & Tokyo, Japan – April 17, 2026 – In a significant move to enhance the precision and efficacy…
Read More
Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
In a significant move poised to accelerate the innovation pipeline for antibody-drug conjugate (ADC) therapies, Japanese pharmaceutical giant Daiichi Sankyo…
Read More
